HPTN 103/Purpose 4
Brief description of study
HPTN 103/PURPOSE 4 is a study being done to see if a twice-a-year medicine that is injected can help reduce the risk of getting HIV from sharing needles for drug use.
Detailed description of study
Every year, many people get HIV. A medicine called lenacapavir (LEN) is being tested to prevent people from getting HIV. This is called pre-exposure prophylaxis (PrEP). This study is being done to understand how LEN moves through the body and understand its safety in people who inject drugs. LEN is approved to treat HIV in adults with limited treatment options, and is being studied in combination with other drugs for treatment of HIV in other populations, and the prevention of HIV. The study will also include Truvada (F/TDF), which is a medicine that we already know is safe and helps to prevent HIV in people who take it every day.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Healthy
-
Age: Between 18 Years - 99 Years
-
Gender: All
- You are a person who injects drugs and have shared injection supplies in the past month.
- You do not have HIV.
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
